COMPANY PROFILE / #2167
Fable Therapeutics
Cambridge, MAVenture Capital-Backed
OVERVIEW
Developer of biologic drugs designed for treating metabolic disease, specifically obesity and related co-morbidities. The company's platform, which is driven by a machine learning-guided protein design approach, integrates AI and advanced computation with extensive datasets of billions of sequences and protein structures to engineer molecules with optimized potency, developability, and binding affinity at the atomic scale, enabling the biotechnology sector to access a new class of precision-engineered medicines with expanded therapeutic potential for complex biological challenges
已融资53.50
最新估值108.50
员工数27
成立年份2020
公司概况
- Companies
- Fable Therapeutics
- Description
- Developer of biologic drugs designed for treating metabolic disease, specifically obesity and related co-morbidities. The company's platform, which is driven by a machine learning-guided protein design approach, integrates AI and advanced computation with extensive datasets of billions of sequences and protein structures to engineer molecules with optimized potency, developability, and binding affinity at the atomic scale, enabling the biotechnology sector to access a new class of precision-engineered medicines with expanded therapeutic potential for complex biological challenges
- Website
- www.fabletherapeutics.com
- HQ Location
- Cambridge, MA
- Year Founded
- 2020
- Keywords
- antibody discovery, biomedicines services, health care, machine learning, protein cell, therapeutic development
- Competitors
- —
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 53.50
- First Financing Date
- 06-Jul-2020
- First Financing Size
- —
- First Financing Valuation
- —
- Last Financing Date
- —
- Last Financing Deal Type
- Later Stage VC
- Last Financing Size
- —
- Last Financing Valuation
- —
- Last Financing Status
- Completed
- Last Known Valuation
- 108.50
- Last Known Valuation Date
- 15-Feb-2024
- Last Known Valuation Deal Type
- Early Stage VC
- Valuation Estimate
- 126.43
- Valuation Estimate Growth Rate
- 16.52%
- Active Investors
- Alexandria Venture Investments, DCVC Bio, MPM BioImpact, Northleaf Capital Partners, University of Toronto, University of Toronto Entrepreneurship, Versant Ventures
- # Active Investors
- 7
- Acquirers
- —
团队与联系人
- Employees
- 27
- Employee Growth %
- -22.86%
- Employee History
- 2026: 27, 2025: 35
- Primary Contact
- David Duvenaud
- Primary Contact Title
- Co-Founder
- Primary Contact Email
- —
- Primary Contact Phone
- —
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- -0.20%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 11
- Size Multiple
- 2.38x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 72
- Majestic Referring Domains
- 26
- SimilarWeb Unique Visitors
- 0
- SimilarWeb Unique Visitors Change
- 0
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 35%
- Success Probability Over Time – 3 Year
- 54%
- Success Probability Over Time – 5 Year
- 64%
记录来源：public.companies · 原始序号 #2167 · 所有字段均按数据库原值展示。